As rumors swirl, Actelion chair says 'no sale'

Actelion reiterated it wants to stay independent despite intense takeover speculation, its top managers told the Financial Times. "The board and management are confident about the future prospects of the company as an independent entity and we're not considering a sale," Chairman Robert Cawthorn told the paper. Report

Suggested Articles

New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.

Following its headline-grabbing presentation at ESC, AZ is out with more data that support Farxiga use in nondiabetic heart failure patients.

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.